Catalyst Pharmaceuticals Executive Compensation (FY24)
CPRX · Executive and director compensation, fiscal 2024 only
The paid brief on Catalyst Pharmaceuticals
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 14, 2026Latest filing (8-K): May 23, 2025
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
187 figures on this page: 178 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
More on Catalyst Pharmaceuticals
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is Catalyst Pharmaceuticals' chief executive and what were they paid?
Richard Daly, Director, President, and Chief Executive Officer, received $7,774,160 in total compensation for fiscal 2024.
What was Catalyst Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 92.7% of votes cast for or against in favor at the meeting held May 20, 2025 for fiscal 2024.
Which companies are in Catalyst Pharmaceuticals' peer group?
The disclosed peer group names Acadia Pharmaceuticals Inc., Amicus Therapeutics, Inc., Amphastar Pharmaceuticals, Inc., Ani Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc., among others.
What is Catalyst Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 21:1 for fiscal 2024, against median employee compensation of $370,800.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Richard Daly Director, President, and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Michael Kalb Executive Vice President, Treasurer, and Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Steven Miller Executive Vice President, Chief Operating Officer, and Chief Scientific Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Jeffrey Del Carmen Executive Vice President, Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Preethi Sundaram Chief Strategy Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Del Carmen | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael W. Kalb | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael W. Kalb | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Preethi Sundaram | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Richard J. Daly | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Steven R. Miller | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Preethi Sundaram | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Jeffrey Del Carmen | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Steven Miller | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Michael Kalb | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Richard Daly | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Jeffrey Del Carmen
Executive Vice President, Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Michael Kalb
Executive Vice President, Treasurer, and Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
Preethi Sundaram
Chief Strategy Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Richard Daly
Director, President, and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Steven Miller
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Patrick J. McEnany Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Molly Harper | ◇ | ◇ | — | — | — | — | ◇ |
Charles B. O'Keeffe | ◇ | ◇ | — | — | — | — | ◇ |
Donald A. Denkhaus | ◇ | ◇ | — | — | — | — | ◇ |
Tamar Thompson | ◇ | ◇ | — | — | — | — | ◇ |
David S. Tierney | ◇ | ◇ | — | — | — | — | ◇ |
Richard J. Daly served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Stock options and RSUs.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Acadia Pharmaceuticals Inc. ACAD
- Amicus Therapeutics, Inc. FOLD
- Amphastar Pharmaceuticals, Inc. AMPH
- Ani Pharmaceuticals, Inc. ANIP
- Collegium Pharmaceutical, Inc. COLL
- Corcept Therapeutics Incorporated CORT
- Dynavax Technologies Corporation DVAX
- Halozyme Therapeutics, Inc. HALO
- Harmony Biosciences Holdings, Inc. HRMY
- Insmed Incorporated INSM
- Ionis Pharmaceuticals, Inc. IONS
- Ironwood Pharmaceuticals, Inc. IRWD
- Pacira BioSciences, Inc. PCRX
- PTC Therapeutics, Inc. PTCT
- Supernus Pharmaceutials, Inc. symbol not shown
- Ultragenyx Pharmaceutical, Inc. RARE
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | May 20, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 21, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | August 22, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | September 19, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | December 3, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | August 20, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 23, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 24, 2018 | = | ◇ | ◇ | ◇ |
| 2015 | June 6, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Catalyst Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Catalyst Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
187 figures on this page: 178 cited to the filing that reported them, 9 calculated from figures it prints.
178 cited to the filing
9 calculated from the filing
Documents cited
- 0001193125-25-125872
- 0001193125-25-079097CEO Pay Ratio · Compensation Discussion and Analysis · Compensation of Directors · Grants of Plan-Based Awards · and 1 more section
- 0001193125-24-144049240 2,859,403 168,196 11,817,471 3.
- 0001193125-23-221544Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-247180
- 0001193125-21-348019
- 0001193125-20-227098
- 0001193125-19-159724
- 0001193125-18-175523
- 0001193125-16-615375
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Catalyst Pharmaceuticals executive compensation, FY2024.” https://intel.velarion.ai/comp/CPRX (accessed 2026).
Short form: data: Velarion
The paid brief for Catalyst Pharmaceuticals
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Catalyst Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Catalyst Pharmaceuticals discloses
The companies named in CPRX's own disclosed peer group.
Acadia Pharmaceuticals Inc.Amicus Therapeutics, Inc.Amphastar Pharmaceuticals, Inc.Ani Pharmaceuticals, Inc.Collegium Pharmaceutical, Inc.Corcept Therapeutics IncorporatedDynavax Technologies CorporationHalozyme Therapeutics, Inc.Harmony Biosciences Holdings, Inc.Insmed IncorporatedIonis Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.Pacira BioSciences, Inc.PTC Therapeutics, Inc.Ultragenyx Pharmaceutical, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}